2 weeks Ago
PetVivo Holdings, Inc. ( OTCPK:PETV ) Q2 2025 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants John Dolan - Chief Business Development Officer and General Counsel John Lai - Chief Executive Officer Garry Lowenthal - Chief Financial Officer Conference Call Participants John Dolan Good afternoon, everyone. Thank you for joining us today to discuss PetVivo's Results for its Fiscal Second Quarter ended September 30, 2024.
Focusing on the call today is our Chief Executive Officer, John Lai; our Chief Financial Officer, Garry Lowenthal; and myself, John Dolan, PetVivo's Chief Business Development Officer and General Counsel. Following our remarks, we'll open the call to your questions. Then before we conclude today's call, I'll provide some important cautions regarding the forward-looking statements made during the call.
I'd like to remind everyone that today's call is being recorded and it will be made available for telecom replay per the instructions in today's press release that is available in the Investor Relations section of our website. Before we provide the financial details for the quarter, I would like to first provide an introductory overview and a few highlights for those new to PetVivo, who have joined us today. In our fiscal second quarter of 2025, we achieved strong financial and operational progress on a number of fronts as we continue to advance the rollout of our flagship product that promotes the restoration of proper joint mechanics, Spryng with OsteoCushion technology.
This injectable intra-articular veterinary device is composed of patented biocompatible microparticles derived from natural resources. The novel technology is a result of years of R&D and independent clinical studies. Spryng's unique, lubricious and viscoelastic characteristics address a prevalent unmet medical need to reduce the joint pain and discomfort caused by osteoarthritis and poor joint biomechanics, afflictions that affect millions of pets and horses worldwide.
.
